Medical devices, healthcare technology and the business of care
510(k) clearance · K262893

Eonis SMA kit

Revvity, Inc. · Decision date Sep 30, 2026

MEDTECHLEDGER EXPLANATIONK262893

What did the FDA decide?

FDA recorded a substantial equivalence determination (SESE) for the Eonis™ SMA kit, submitted by Revvity, Inc., with a decision date of 2026-09-30 under 510(k) number K262893. The product code is QUE, regulation 21 CFR 866.5980, in the Immunology specialty. The submission's stated purpose was adding a new instrument to the test system, the Eonis Q instrument, paired with Eonis EASI software. The predicate is the Eonis SCID-SMA Kit under DEN200044.

The kit is intended for qualitative detection of SMN1 gene exon 7 as an aid in newborn screening for spinal muscular atrophy, using DNA from dried blood spots; the labeling states it is not a diagnostic test and that positive screening results should be followed by confirmatory testing. The decision summary describes a site-to-site reproducibility study across three sites and reports 100% of replicates below cut-off for the listed samples, with a 95% CI of 97.6% to 100%. The source does not state clinical sensitivity or specificity, and the decision is a clearance, not a PMA approval.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Immunology
Decision date
Sep 30, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262893
Regulatory pathway
510(k) premarket notification
Applicant
Revvity, Inc.
Product code
QUE
Decision code
SESE
Decision date
Sep 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Spinal Muscular Atrophy Newborn Screening Test System.

Applicant
Revvity, Inc.
Product code
QUE
FDA device class
2

FDA decision timeline

  1. K262893 received

    Application receipt date recorded by FDA.

  2. K262893 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Revvity, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Waltham, MA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records